

Remarks

Applicants thank the Examiner for his helpful comments in the telephone call on October 24, 2006. Applicant has relied on such comments to amend the claims and advance prosecution. Claims 14, 27 and 34 have been amended to incorporate the feature that the claimed nucleic acid encode a protein with a defined function in addition to the recited structural features. Written support for the amendments can be found throughout the specification including, for example, at page 21, lines 6 to 9. No new matter has been introduced by these amendments.

Rejection under 35 U.S.C. 101

The Examiner has rejected claims 14 to 34 because the claimed invention is allegedly not supported either by a specific and substantial asserted utility or by a well established utility under 35 U.S.C. 101. The Examiner has also rejected claims 14 to 34 under 35 U.S.C. 112, first paragraph, because the specification allegedly does not adequately disclose to the skilled person how to use the claimed invention.

Applicants provide herewith a declaration by the inventor, Brian O'Dowd which sets forth the utility of the claimed invention. Specifically, the claimed invention finds utility in the treatment of sexual disorders (*i.e.*, hypogonadotrophic hypogonadism) in humans. As set forth in the attached declaration, individuals who suffer from hypogonadotrophic hypogonadism do not express a functional GPR54 receptor. The nucleic acids of the invention therefore derive therapeutic utility in that they can be used in gene therapy to express active GPR54 receptor in a subject suffering from a sexual disorder (*e.g.*, hypogonadotrophic hypogonadism).

Applicants bring to the attention of the Examiner that the specification discloses that gene therapy using the claimed nucleic acids will be particularly useful in the treatment of diseases where it is beneficial to elevate GPR54 activity (see page 28, lines 9 to 19). Applicants further identify treatment of diseases that involve inappropriate expression of GPR54 including sexual disorders (*i.e.*, hypogonadotrophic hypogonadism) as a utility of the claimed invention (see page 24, lines 17 to 25).

Applicants also bring to the attention of the Examiner that in each of the publications cited in the attached declaration, the normal sequence of GPR54 was essential in discovering the mutant forms of GPR54 associated with hypogonadotrophic hypogonadism. Specifically, oligonucleotides based on the GPR54 gene sequence were used to isolate the mutant forms of the

gene and by comparing the nucleotide sequences of the genes isolated from the patients with hypogonadotropic hypogonadism with the normal GPR54 gene sequence, the mutations responsible for this disease were identified. The specification discloses that oligonucleotides can be used to isolate DNA encoding the GPR54 receptor (see page 28, lines 20 to 32). Applicants therefore submit that these oligonucleotides can be used in the diagnosis of sexual disorders such as hypogonadotrophic hypogonadism.


Applicants specification also discloses that the GPR54 gene is located on chromosome 19p13.3 and that this information can be used in linkage analysis studies to correlated the location of disease causing genes to the location of the GPR54 gene (see page 26, line 18 to page 27, line 10). The attached peer-reviewed journal publication by de Roux *et al.* (2003) demonstrates that this information was utilized to identify the locus for hypogonadotropic hypogonadism on chromosome 19 (19p13). Subsequent sequencing experiments determined that the GPR54 gene (found in this region) contains defects in siblings of a family suffering from hypogonadotropic hypogonadism. Applicants therefore submit that the claimed invention finds utility in the identification and diagnosis of sexual disorders such as hypogonadotrophic hypogonadism. In view of the above arguments, Applicants submit that the rejections under 35 U.S.C. 101 and 112, first paragraph are moot and withdrawal is requested.

Applicants request reconsideration of the subject application in view of the above remarks and withdrawal of the rejections. It is respectfully submitted that this application is now in condition for allowance. Should the Examiner believe it to be useful, an interview with the Examiner is respectfully requested in order to discuss the foregoing claims.

If there are any fees due in connection with the filing of this amendment, please charge the fees to our Deposit Account No. 50-310. If a fee is required for an extension of time under 37 C.F.R. 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **November 20, 2006**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP


Robert Smyth
Registration No. 50,801

Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54

Nicolas de Roux^{*,†}, Emmanuelle Genin[‡], Jean-Claude Carel[§], Fumihiko Matsuda^{||}, Jean-Louis Chaussain[¶], and Edwin Milgrom^{*}

^{*}Institut National de la Santé et de la Recherche Médicale Unité 135, Unité de Recherches Hormones Gènes et Reproduction, Hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France; [†]Institut National de la Santé et de la Recherche Médicale Unité 584, Hormone Targets, Faculté de Médecine Necker Enfants Malades, 75015 Paris, France; [‡]Institut National de la Santé et de la Recherche Médicale Unité 535, Génétique Epidémiologique et Structure des Populations Humaines, Hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France; [§]Service d'Endocrinologie Pédiatrique, Hôpital Saint Vincent de Paul, 75014 Paris, France; and ^{||}Centre National de Genotypage, 2 Rue Gaston Cremieux, 91057 Evry, France

Communicated by Etienne-Emile Baulieu, Collège de France, Le Kremlin-Bicêtre Cedex, France, July 14, 2003 (received for review June 16, 2003)

Hypogonadotropic hypogonadism is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function. In the absence of pituitary or hypothalamic anatomical lesions and of anosmia (Kallmann syndrome), hypogonadotropic hypogonadism is referred to as isolated hypogonadotropic hypogonadism (IHH). A limited number of IHH cases are due to loss-of-function mutations of the gonadotropin-releasing hormone receptor. To identify additional gene defects leading to IHH, a large consanguineous family with five affected siblings and with a normal gonadotropin-releasing hormone receptor coding sequence was studied. Homozygosity whole-genome mapping allowed the localization of a new locus within the short arm of chromosome 19 (19p13). Sequencing of several genes localized within this region showed that all affected siblings of the family carried a homozygous deletion of 155 nucleotides in the *GPR54* gene. This deletion encompassed the splicing acceptor site of intron 4–exon 5 junction and part of exon 5. The deletion was absent or present on only one allele in unaffected family members. *GPR54* has been initially identified as an orphan G protein-coupled receptor with 40% homology to galanin receptors. Recently, a 54-aa peptide derived from the KiSS1 protein was identified as a ligand of *GPR54*. The present study shows that loss of function of *GPR54* is a cause of IHH, and it identifies *GPR54* and possibly KiSS1 protein-derived peptide as playing a major and previously unsuspected role in the physiology of the gonadotropic axis.

The integrity of the pituitary–gonadal axis allows normal sexual differentiation during fetal life and normal puberty and fertility (1–3). Hypogonadotropic hypogonadism is defined by a defect of gonadal functions manifested by impuberty, partial pubertal development or isolated infertility, caused by a deficiency of follicle-stimulating hormone and luteinizing hormone production. The biological hallmark is a decreased level of sex steroids associated with low or normal levels of follicle-stimulating hormone and luteinizing hormone. This profile can result from deficiencies in gonadotropin-releasing hormone (GnRH) production by the hypothalamus, in GnRH receptor function at the pituitary level, or in luteinizing hormone and follicle-stimulating hormone production by the pituitary. Hypogonadotropic hypogonadism can result from tumoral, surgical, or physical insults at the hypothalamic or pituitary level and is generally associated with other pituitary hormone deficiencies. Hypogonadotropic hypogonadism can be part of multiple pituitary hormone deficiencies associated with genetic defects of transcription factors such as *PROP1*, *HESX1*, *LHX3*, and *LHX4* or with developmental abnormalities of the region, such as pituitary stalk interruption syndrome (4). Hypogonadotropic hypogonadism can be associated with anosmia (Kallmann syndrome) or apparently

isolated without anosmia [isolated hypogonadotropic hypogonadism (IHH)] (5). Kallmann syndrome is itself heterogeneous with an X-linked form due to mutations in *Kal1*, the gene encoding for anosmin (6, 7), and forms with autosomal transmission. Loss-of-function mutations of the fibroblast growth factor receptor 1 have recently been associated with ~10% of autosomal forms of Kallmann syndrome (8). In 1997, the first cases of IHH due to loss-of-function mutations of the GnRH receptor gene were reported by our group (9). However, GnRH receptor mutations account for <50% of familial IHH cases and a small fraction of sporadic cases, indicating that IHH is a heterogeneous condition caused by various genetic defects (10).

In this study, a large consanguineous family comprising five siblings with IHH led us to identify, by a genome-mapping strategy, the G protein-coupled receptor 54 (*GPR54*) as a protein involved in the regulation of gonadotropin secretion.

Subjects, Materials, and Methods

Subjects. A consanguineous family of eight children of whom five were affected was investigated (Fig. 1). The parents were first cousins. The index case was a 20-year-old male referred for impuberty. He had typical signs of hypogonadism with small testes (4 ml), sparse pubic hair (P3), and a penis of 7 cm. His height and weight were 152 cm and 54 kg, respectively, and his bone age was retarded at 15.0 years. He had a normal sense of smell and showed no abnormal eye movements, no color blindness, and no renal or craniofacial abnormalities. Three brothers had similar clinical features. A sister had partial hypogonadism; at age 16 years she had partial breast development and had experienced a single episode of uterine bleeding. Hormonal measurements (Table 1) showed low plasma testosterone in affected males and low plasma estradiol in the affected female, associated with low plasma gonadotropin levels. All affected siblings had a blunted response to GnRH (100 μ g i.v.). One brother and two sisters had normal pubertal development. The mother had menarche at the age of 16 years. The father reported normal pubertal development. All patients and family members gave written informed consent for genetic analyses.

Genotyping. Genomic DNA was isolated from peripheral lymphocytes by using standard methods. Genotyping was conducted at the Genopole in Evry, France. A genomewide analysis was performed by using the Genethon panel with microsatellite markers spaced, on average, ~15 centimorgans apart (11). For fine mapping, we used

Abbreviations: IHH, isolated hypogonadotropic hypogonadism; GnRH, gonadotropin-releasing hormone; *GPR54*, G protein-coupled receptor 54.

^{*}To whom correspondence should be addressed. E-mail: deroux@necker.fr.

© 2003 by The National Academy of Sciences of the USA




Fig. 1. Haplotypes. The common haplotype shared by both parents is shown in gray boxes. IHH2.1, IHH2.2, and IHH2.3 are new CA repeat markers selected in the region of interest. A horizontal line shows the location of the recombination event in patient III.4.

other microsatellite markers published elsewhere (12) and new informative CA repeat markers (HH2.1, HH2.2, and HH2.3) that we identified from contigs localized within the region of interest. The primer sequences of these markers are listed in Table 2.

Linkage Analysis. Two-point logarithm of odds (lod) scores were computed by using FASTLINK 4.1P (13, 14) and multipoint lod scores were computed by using GENEHUNTER 2.0 (15). The disease gene was assumed to be fully penetrant, autosomal, and recessive (frequency, 0.00001). Frequencies of the marker allele were varied to study the robustness of the results. All results are reported assuming equiprobable alleles (frequency, 0.25) at each marker. For multipoint analysis, genetic distances between markers were derived from the Genethon map (11).

Sequencing. The five exons of the *GPR54* gene were amplified by PCR with 20–100 ng of genomic DNA. The following primers

were used. Exon 1: forward, GGGCGGCCGGGAGGAGGA; reverse, CCGGGACGGCAGCAGGTG. Exon 2: forward, GCCCAGCGCCCCGCGCATC; reverse, GTCCCCAAGTGCGCCCTCTC. Exon 3: forward, CAGGCTCCCAACCGCGCAG; reverse, CGTGTCCGCCTTCTCCCGTG. Exon 4: forward, CTTTCATCCTGGCTTGTGGCAC; reverse, CTTGCTGTCCTCCACCCAC. Exon 5: forward, GCCTTCGTCTAACACCTTC; reverse, GGAGCCGCTCGGA-TTCCCAC. Amplification was performed for 30 cycles with Yellow *Taq* (Eurogentec, Brussels) in 1.5 mM MgCl₂, with 0.1 μM each primer and 5% DMSO. The annealing temperatures were 60°C for exons 1, 3, 4, and 5 and 66°C for exon 2. The PCR products were directly sequenced with BigDye dideoxyterminator cycle sequencing kits and the 3100 sequencer (Applied Biosystems) with the same primers. To genotype all members of the family, the PCR products of exon 5 were analyzed by electrophoresis in a 2% agarose gel.

Table 1. Hormonal status of affected siblings

Subjects (gender)	Age, yr	Bone age, yr	Plasma testosterone, ng/dl	Plasma estradiol, pg/ml	Plasma LH, milliunits/ml	Plasma FSH, milliunits/ml	GnRH test	
							LH	FSH
III.2 (m)	21	15	26	–	1.5	0.5	3.6	1.7
III.3 (m)	20	15	19	–	1.5	0.5	1.4	1.5
III.4 (m)	19	–	5	–	1.1	4.1	1.9	4.1
III.6 (f)	18	–	–	17	2.0	3.4	11.8	6.4
III.7 (m)	14	11	5	–	2.6	1.8	3.4	2.6

The chronological and bone ages are indicated. Normal values: males, luteinizing hormone (LH), 1.0–5.0 units/ml; follicle-stimulating hormone (FSH), 0.9–5.7 units/ml; testosterone, 260–690 ng/dl. Females, LH, 1.1–5.4 units/ml; FSH, 2.3–6.0 units/ml; estradiol (early follicular phase), 25–90 pg/ml. The GnRH test was performed by intravenous administration of 100 μg of GnRH. The highest values observed for plasma LH and FSH are reported. m, male; f, female.

Table 2. Primer sequences of the new CA repeats used in the fine mapping

Primer name	Sequences	Genomic contig	Position of the 5' nucleotide of the primer
IHH2.1F	CCAAGATCACAACCTGCAC	NT.011255.13	552 360
IHH2.1R	ACCTGATAGTCTGACCGAAT	NT.011255.13	552 486
IHH2.2F	CACGGAAGGGAAGCAACCAT	NT.011255.13	1 594 931
IHH2.2R	TGATCTCACCCTGCACTCC	NT.011255.13	1 595 035
IHH2.3F	ATAAATAAAGTGGCCAGGA	NT.011255.13	1 718 816
IHH2.3R	GGGTCCGGAACAGGTAG	NT.011255.13	1 718 933

Results

GnRH Receptor Genotyping. DNA was extracted from blood lymphocytes of the index case, and the GnRH receptor exons were sequenced and found to be normal. Two-point linkage analysis performed with markers localized on chromosome 4 allowed the definitive elimination of any anomaly of the GnRH receptor locus in this family (logarithm of odds score less than -2).

Genome Mapping. The large size of the family with numerous affected individuals and the high consanguinity allowed a homozygosity mapping strategy to localize the genomic region harboring the disease-causing allele. Preliminary computer analysis gave an 85% probability of finding the locus of interest (16)

(data not shown). Two hundred eighty-two markers encompassing all autosomes were used for genome mapping (11). Only one marker, *D19S886*, was homozygous in all affected patients and was heterozygous in both parents. The logarithm of odds score for *D19S886* was 3.5 at $\theta = 0$, indicating a strong probability of linkage. A recombination event was found in patient III.4 between markers *D19S886* and *D19S424* (Fig. 1). *D19S886* was the most telomeric marker used on the short arm of chromosome 19. The disease-causing genetic lesion was thus localized between the telomere (pTer) and *D19S424*. This region was called IHH2, spanning 14 centimorgans in genetic maps. We narrowed this interval by using four additional published markers (11, 12) and three previously undescribed polymorphic CA repeats (IHH2.1, IHH2.2, and IHH2.3) selected in the contigs localized

Chromosome 19




Fig. 2. (Upper) Localization and sequencing of the *GPR54* gene. Markers used in the genotyping and the recombination point in patient III.4 are indicated. (Lower) DNA sequences from unaffected sib III.1 and affected patient III.2 are shown. The primers used for amplification of exon 5 were localized within intron 4 and in the 3' untranslated region. The cDNA numbering was used to designate nucleotides in exon 5. In intron 4, nucleotides were numbered starting from the end of the intron. Residues of the 3' end of intron 4 present in both individuals are underlined.




Fig. 3. Genotyping of exon 5 in family. Exon 5 was amplified from genomic DNA. The PCR products (size in wild-type gene, 524 bp) were analyzed in 2% agarose gel.

within IHH2. Fine mapping using these markers assigned the recombination point to an interval of 110 kbp delimited by IHH2.2 and IHH2.3 (Fig. 2 Upper). The length of the interval of interest was estimated at 1,650 kbp (*Homo sapiens* Map View, Build 30; www.ncbi.nlm.nih.gov/mapview/maps.cgi).

Sequencing of *GPR54* Gene. Candidate genes present in the region of interest and potentially involved in reproduction, signaling, and development were sequenced. No difference was found between DNA from affected and nonaffected individuals in *EPLG6*, *BSG*, *FSTL3*, and *NR3B* genes (17–20). When amplifying exon 5 of the *GPR54* gene of affected patients, we observed a single PCR product smaller than that of control subjects (Fig. 3). Exon 5 PCR amplification of DNA from both parents and from the unaffected sibling III.5 showed a band of the normal size and the smaller band. DNA from the unaffected sibling III.1 gave only the normal size band. A normal pattern of exon 5 PCR amplification was found in DNA from 50 control subjects. These results were consistent with the mapping data and suggested that a deletion within exon 5 of the *GPR54* gene was linked to IHH in this family.

Sequencing of the smaller PCR product amplified from affected patients showed a deletion of 155 bp lying between intron 4 (nucleotide –13 when numbering from the 3' end of intron 4) and exon 5 (nucleotide 142 of exon 5, corresponding to nucleotide 880 of the cDNA) (Fig. 2 Lower). Sequencing of exon 5 in DNA amplified from the unaffected sibling III.5 confirmed the heterozygosity for the 155-bp deletion.

Discussion

In this paper, we show that a *GPR54* gene defect leads to isolated hypogonadotropic hypogonadism. *GPR54* is a G protein-coupled receptor initially cloned in the rat by using degenerate primers based on conserved sequences present in transmembrane domains (21). It has a 40% homology with galanin receptors. *GPR54* was thereafter cloned in humans (called hOT7T175 or Axor-12) and found to be expressed mainly in the brain, pituitary, and placenta (22–24). *GPR54* is formed of five exons. The deletion we have observed removes the splicing acceptor site of intron 4–exon 5 junction and part of exon 5 (Fig. 2 Upper). This deletion thus leads to the absence of the normal protein sequence downstream from residue 247. The deleted receptor is

truncated within the third intracellular loop, thus lacking transmembrane domains 6 and 7. It has been shown that such truncated G protein-coupled receptors are unable to stimulate the transduction pathway (25). It is unknown whether the gene deletion present in this family leads to the absence of protein synthesis or to the synthesis of a truncated protein.

Recently, a ligand binding to *GPR54* was described independently by three groups. Kotani *et al.* (22) and Ohtaki *et al.* (23) analyzed placental extracts for peptides activating *GPR54*. Muir *et al.* (24) used a library of 1,500 putative ligands. The best agonists displayed a similarity to a 54-aa peptide derived from the KiSS1 protein (26). This peptide corresponds to the predicted proteolytic processing of KiSS1 at dibasic and dibasic/amidation sites. It displays a C-terminal LRF-amide sequence. *GPR54* stimulation by this 54-aa peptide results in the activation of phospholipase C by coupling to a Gq protein. KiSS1 mRNA is mainly present in the placenta and brain (24). In the brain, it has been localized to the hypothalamus and basal ganglia.

In support of our findings, we have sequenced the *GPR54* gene in three other familial cases of isolated hypogonadotropic hypogonadism and found one missense homozygous point mutation (Leu102Pro). However, in contrast to deletions, point mutations must be expressed in transfected cells and shown to functionally impair the receptor. The Leu102Pro mutation in the *GPR54* gene was not observed in 50 control subjects. Further studies of familial and sporadic cases of IHH will be necessary before assessing the frequency of *GPR54* gene defects.

GPR54, initially described as an orphan receptor (21), binds a 54-aa RF-amide peptide derived by proteolysis from the KiSS1 protein (22–24). Our results show that *GPR54* and possibly KiSS1-derived peptide play an important and previously unsuspected role in the physiology of the gonadotropic axis.

In conclusion, the present study shows that a genetic alteration leading to homozygous loss of function of *GPR54* impairs pubertal development and reproductive functions. This finding indicates that *GPR54* plays an important and previously unsuspected role in the regulation of the gonadotropic axis. The KiSS1 gene product is a RF-amide peptide, and two peptides with structural similarities have recently been shown to play a role in neuroendocrine regulations (27, 28). KiSS1 gene was initially cloned as a tumor metastasis suppressor gene (26), and the mature protein was named metastin. Activation of *GPR54* by metastin results in decreased cellular motility (23) and proliferation (22, 23). Metastin is also believed to control the migration of trophoblast cells (29). However, it is unknown whether these features are relevant to the mechanisms leading to IHH in our patients. Moreover, further work is needed to determine whether *GPR54* loss-of-function mutations affect the gonadotropic function at the hypothalamic or pituitary level. These findings suggest that a new chapter may thus be opened in the physiology of the gonadotropic axis.

We thank Odile Tinmar and Sylvain Goudet (Laboratoire d'Hormonologie et Biologie Moléculaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France) for their help with DNA sequencing, and Professors J. L. de Gennes and Paul Kelly for helpful discussions.

- Achermann, J. C., Ozisik, G., Meeks, J. J., & Jameson, J. L. (2002) *J. Clin. Endocrinol. Metab.* 87, 2447–2454.
- Themmen, A. P. N., & Huhtaniemi, I. T. (2000) *Endocr. Rev.* 21, 551–583.
- Kalantaridou, S. N., & Chrousos, G. P. (2002) *J. Clin. Endocrinol. Metab.* 87, 2481–2494.
- Cohen, L. E., & Radovick, S. (2002) *Endocr. Rev.* 23, 431–442.
- Seminara, S. B., Hayes, F. J., & Crowley, W. F., Jr. (1998) *Endocr. Rev.* 19, 521–539.
- Franco, B., Guioli, S., Pragliola, A., Incerti, B., Bardoni, B., Tonlorenzi, R., Carrozzo, R., Maestrini, E., Pieretti, M., Taillon-Miller, P., *et al.* (1991) *Nature* 353, 529–536.
- Legouis, R., Hardelin, J. P., Levilliers, J., Claverie, J. M., Compain, S.,

- Wunderle, V., Millasseau, P., Le Paslier, D., Cohen, D., Caterina, D., *et al.* (1991) *Cell* 67, 423–435.
- Dode, C., Levilliers, J., Dupont, J. M., De Paepe, A., Le Du, N., Soussi-Yanicostas, N., Coimbra, R. S., Delmaghani, S., Compain-Nouaille, S., Baverel, F., *et al.* (2003) *Nat. Genet.* 33, 463–465.
- de Roux, N., Young, J., Mirrahi, M., Genet, R., Chanson, P., Schaison, G., & Milgrom, E. (1997) *N. Engl. J. Med.* 337, 1597–1602.
- Beranova, M., Oliveira, L. M., Bedecarrats, G. Y., Schipani, E., Vallejo, M., Ammini, A. C., Quintos, J. B., Hall, J. E., Martin, K. A., Hayes, F. J., *et al.* (2001) *J. Clin. Endocrinol. Metab.* 86, 1580–1588.
- Dib, C., Faure, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Hazan, J., Seboun, E., *et al.* (1996) *Nature* 380, 152–154.

12. Collin, G. B., Munch, A., Mu, J. L., Naggert, J. K., Olsen, A. S. & Nishina, P. M. (1996) *Genomics* 37, 125–130.
13. Cottingham, R. W., Jr., Idury, R. M. & Schaffer, A. A. (1993) *Am. J. Hum. Genet.* 53, 252–263.
14. Schaffer, A. A., Gupta, S. K., Shriram, K. & Cottingham, R. W., Jr. (1994) *Hum. Hered.* 44, 225–237.
15. Kruglyak, L., Daly, M. J., Reeve-Daly, M. P. & Lander, E. S. (1996) *Am. J. Hum. Genet.* 58, 1347–1363.
16. Genin, E., Todorov, A. A. & Clerget-Darpoux, F. (1998) *Ann. Hum. Genet.* 62, 419–429.
17. Chatterton, J. E., Awobuluyi, M., Premkumar, L. S., Takahashi, H., Talantova, M., Shin, Y., Cui, J., Tu, S., Sevarino, K. A., Nakanishi, N., *et al.* (2002) *Nature* 415, 793–798.
18. Drescher, U. (1997) *Curr. Biol.* 7, R799–R807.
19. Fan, Q. W., Yuasa, S., Kuno, N., Senda, T., Kobayashi, M., Muramatsu, T. & Kadomatsu, K. (1998) *Neurosci. Res.* 30, 53–63.
20. Guo, Q., Kumar, T. R., Woodruff, T., Hadsell, L. A., DeMayo, F. J. & Matzuk, M. M. (1998) *Mol. Endocrinol.* 12, 96–106.
21. Lee, D. K., Nguyen, T., O'Neill, G. P., Cheng, R., Liu, Y., Howard, A. D., Coulombe, N., Tan, C. P., Tang-Nguyen, A. T., George, S. R., *et al.* (1999) *FEBS Lett.* 446, 103–107.
22. Kotani, M., Dethoux, M., Vandenbogaerde, A., Communi, D., Vanderwinden, J. M., Le Poul, E., Brezillon, S., Tyldesley, R., Suarez-Huerta, N., Vandeput, F., *et al.* (2001) *J. Biol. Chem.* 276, 34631–34636.
23. Ohtaki, T., Shintani, Y., Honda, S., Matsumoto, H., Hori, A., Kanchashi, K., Terao, Y., Kumano, S., Takatsu, Y., Masuda, Y., *et al.* (2001) *Nature* 411, 613–617.
24. Muir, A. I., Chamberlain, L., Elshourbagy, N. A., Michalovich, D., Moore, D. J., Calamari, A., Szekeres, P. G., Sarau, H. M., Chambers, J. K., Murdock, P., *et al.* (2001) *J. Biol. Chem.* 276, 28969–28975.
25. Gether, U. (2000) *Endocr. Rev.* 21, 90–113.
26. Lee, J. H., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E. & Welch, D. R. (1996) *J. Natl. Cancer Inst.* 88, 1731–1737.
27. Satake, H., Hisada, M., Kawada, T., Minakata, H., Ukena, K. & Tsutsui, K. (2001) *Biochem. J.* 354, 379–385.
28. Hinuma, S., Habata, Y., Fujii, R., Kawamata, Y., Hosoya, M., Fukusumi, S., Kitada, C., Masuo, Y., Asano, T., Matsumoto, H., *et al.* (1998) *Nature* 393, 272–276.
29. Janneau, J. L., Maldonado-Estrada, J., Tachdjian, G., Miran, I., Motte, N., Saulnier, P., Sabourin, J. C., Cote, J. F., Simon, B., Frydman, R., *et al.* (2002) *J. Clin. Endocrinol. Metab.* 87, 5336–5339.